(Credit-Canva)
Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!
The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.
"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.
The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.
While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.
And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.
Credit: AI
Breast cancer diagnosed shortly after pregnancy may be more aggressive. According to new research, some young mothers may face poorer outcomes despite having similar types of breast cancer tumors as other women.
A UCLA-led study, published in npj Breast Cancer, found that women diagnosed with hormone receptor-positive (HR+), HER2-negative breast cancer within the first three years after childbirth, especially during the first year, were more likely to have tumors with a higher risk of recurrence.
It therefore indicates that postpartum breast cancer is not simply breast cancer diagnosed after pregnancy but may be a biologically distinct disease.
Researchers analyzed young women with HR-positive, HER2-negative breast cancer using the widely used 21-gene Oncotype DX Recurrence Score, a genomic test that helps predict the likelihood of cancer recurrence and whether chemotherapy may be beneficial.
They discovered that tumors diagnosed during the first three years after childbirth had significantly higher recurrence rates than tumors in women who had never given birth.
The highest scores were observed among women diagnosed within the first year after delivery.
"Our findings suggest that the first three years after childbirth represent a distinct biological window during which hormone receptor-positive breast cancers may behave more aggressively," the researchers observed.
The study also provides one of the first genomic definitions of this high-risk postpartum period rather than relying solely on clinical observations.
Also read: You Know What? Wearing Black Underwears Do Not Cause Breast Cancer - Myths Busted By Expert
Researchers believe that the answer to that question lies in what happens to the breast after breastfeeding comes to an end.
After pregnancy and lactation, the breast undergoes a natural process called mammary gland involution, during which the milk-producing tissue shrinks, and the breast returns to its pre-pregnancy state.
While this change is normal, it creates a temporary environment that features inflammation, weakened immune system, and extensive tissue restructuring.
According to a recent review published in Breast Cancer Research, these biological changes may unintentionally create conditions that help dormant cancer cells survive, grow, and spread. Researchers describe this postpartum remodeling as a "tumor-promoting microenvironment."
These processes may partly explain why postpartum breast cancers are often diagnosed at more advanced stages and have poorer outcomes than breast cancers in women of similar age who have not recently given birth.
The findings hold importance as breast cancer rates among younger women continue to increase worldwide just when women are getting pregnant later in their lives. Previous studies have indicated that breast cancer detected after pregnancy behaves differently.
"The medical community has long recognized that breast cancers diagnosed after pregnancy can behave differently," UCLA researchers said. "With breast cancer rates among younger women increasing, scientists have been studying whether delayed timing of first pregnancy may help explain some of that trend."
Because pregnancy and breastfeeding naturally change breast tissue, warning signs like lumps or breast firmness can sometimes be mistaken for normal postpartum changes. This may delay diagnosis and allow cancers to progress before they are detected.
Credit: iStock
Every baby born in England will be offered a life-saving genetic screening test for spinal muscular atrophy (SMA) from October 2027, the UK Department of Health and Social Care announced on Thursday.
The government said it will expand newborn screening for SMA across the country as part of a national evaluation program. The rollout will begin later this year, with hundreds of thousands of babies expected to be screened before universal coverage is achieved in 2027.
The decision follows campaigning for universal newborn screening by former Little Mix singer Jesy Nelson, whose twin daughters, Ocean Jade and Story Monroe Nelson, were diagnosed with the rare muscle-wasting disorder.
Calling it a "day of hope", Nelson called the move a "victory for every family affected by SMA".
Also read: Meet Erica Schwartz: Trump's CDC Nominee Who Pledges to 'Never Betray Science'
The SMA screening evaluation program will begin across England in autumn 2026, with laboratories starting to test newborns from October 2026—three months earlier than originally planned after the government committed to accelerating the rollout.
Almost 72% of newborns in England are already due to be tested from October under a pilot program announced in April.
From October 2027, screening will be expanded to all babies born in England, covering an estimated 560,000 to 570,000 newborns every year. Universal coverage will be achieved by increasing the number of laboratories able to carry out the testing from seven to 13.
The screening will use the routine heel-prick blood test, performed when babies are five days old.
A small blood sample collected through the heel prick will be tested for SMA alongside the 10 conditions already included in the newborn screening program, such as:
Read More: Babies Without Vitamin K Shot At Higher Risk Of Brain Bleeding: Study
SMA can leave babies unable to sit up, crawl or walk. In its most severe forms, it can also affect breathing and swallowing.When diagnosed early, babies can receive effective treatment—including gene therapy—which can significantly improve outcomes.
"No parent should have to watch their child lose the ability to move or breathe, knowing that earlier treatment could have made all the difference," said James Murray, Secretary of State for Health and Social Care.
Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder caused by mutations in the SMN1 gene, resulting in a deficiency of the SMN protein.
The condition causes the progressive loss of motor neurons in the spinal cord, leading to severe muscle weakness and muscle wasting.
Babies with SMA may have:
If left undiagnosed and untreated, the most severe forms of SMA can be fatal within the first two years of life.
SMA affects around one in every 10,000 babies, with approximately 48 babies diagnosed each year in the UK.
Health officials say newborn screening will allow affected babies to receive life-changing treatment before symptoms develop.
"This is a hugely important step forward. When newborn screening for SMA begins later this year in October, thousands of babies will benefit from earlier diagnosis and access to life-changing treatment," said Giles Lomax, Chief Executive of Spinal Muscular Atrophy UK, while welcoming the announcement.
Credit: AI
Sleep disorders have long been associated with daytime fatigue, poor concentration, and memory problems. Now, a new neuroimaging study suggests that the impact of sleep disorders could be deeper.
Researchers have found that people with sleep disorders show structural changes in brain regions involved in attention, motivation, decision-making, and emotional regulation.
The findings, published in the Nature Portfolio journal Scientific Reports, are based on one of the largest neuroimaging meta-analyses examining structural changes in the brain across multiple sleep disorders.
Researchers analyzed data from numerous brain imaging studies involving people diagnosed with various sleep disorders. The following alterations were absorbed in different regions of the brain:
According to the researchers, disrupted sleep may interfere with the brain's ability to maintain biological functions.
Rather than affecting a single region, sleep disorders appear to impact multiple interconnected networks in the brain.
This could be why many people with chronic sleep disorders experience symptoms beyond tiredness. Some of them are:
Also read: Pediatric Sleep: The Foundation Of Healthy Growth, Behavior And Society
These symptoms are commonly reported in conditions like insomnia, obstructive sleep apnea, restless legs syndrome, and other chronic sleep disorders.
The new study adds to the evidence that healthy sleep is essential for maintaining optimum cognitive function.
Previous studies have linked sleep deprivation to poor attention, slower reflexes, increased dementia risk, and poor emotional processing.
They have also indicated that even chronic sleep deprivation can contribute to changes in brain health alongside metabolic and cardiovascular effects.
Also read: Why Are Sleep Disorder Cases Rising In Children Under 10 In South Korea?
In an earlier study, researchers discovered that even just three nights of insufficient sleep were enough to change blood chemistry, affecting heart health.
In the study, it was observed that the levels of proteins linked to a higher risk of heart disease and inflammation went up after just three nights of poor sleep.
It was further observed that while exercise had some positive effects on protein levels, it wasn't enough to completely eliminate the harm caused by not sleeping enough. Even with exercise, participants still showed increased levels of 16 proteins associated with heart disease.
The study points out how young and healthy people can face these negative biological changes from short-term sleep loss.
Persistent problems with falling asleep, staying asleep, excessive daytime sleepiness, or interrupted breathing during sleep deserve immediate medical attention.
As researchers continue to unravel how sleep shapes the brain, one message has become increasingly clear: quality sleep is not simply a time of rest. It is an essential biological process that supports physical health, attention span, decision-making, emotional well-being, and overall cognitive health.
© 2024 Bennett, Coleman & Company Limited